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Letters to the Editor
588Which transarterial therapy is best for hepatocellular
carcinoma? – The evidence to dateTo the Editor:
We read with interest the recently published randomised con-
trol trial (RCT) of transarterial chemoembolization (TACE) vs.
transarterial chemotherapy (TAI) [1] for hepatocellular carci-
noma (HCC), and the accompanying editorial [2]. The authors
addressed a long-standing debate on whether the combination
of chemotherapy and embolization is more effective than either
therapy alone. They found no difference between TACE and TAI
with regards to patients’ survival. We agree with the editorial
that the results are confounded by the low number of protocol
treatments and the high percentage of patients with advanced
tumours who are unlikely to respond. However, there are fur-
ther issues not raised in the editorial, which also confound the
interpretation of this randomised study, and transarterial ther-
apy for HCC in general.
Firstly, TACE is not a standardised procedure [3] with differ-
ent embolic and chemotherapeutic agents, different arterial
selectivity before embolisation, and different schedules and
indications for repeat sessions. Indeed, gelatine sponge parti-
cles, the most common embolizing agent used in previous
RCTS, only provides short-term artery occlusion that lasts at
most for 2 weeks, whereas polyvinyl alcohol particles (PVA),
now used in many centres, result in permanent artery occlu-
sion [3].
Apart from the duration and effectiveness of the embolisation,
the value of the current chemotherapeutic agents has little evi-
dence to support their use. Firstly, these same agents are not
effective if given systematically with similar systemic concentra-
tions when given intra-arterially [4]. Secondly, there are now
three published RCTs of transarterial embolisation alone (TAE)
versus TACE, all using the sub-optimal gelatine sponge in both
arms [5–7]; a metanalysis shows no difference in survival [3].
Given the side effects of the chemotherapeutic agents, their use
must be questioned. Lastly, we have shown in our meta-analysis
that TAI has no effect [3].
The new drug eluting beads (DEBs) favoured in the editorial as
the optimal transarterial approach, undoubtedly limit the sys-
temic side effects of TACE but are not more effective as shown
in a recent randomised study [8]. In addition, there is no random-
ised study in patients, of bland beads alone, and neither versus
PVA particles in TAE. PVA particles could represent the optimal
embolizing agent due to the permanence of arterial occlusion
[3] and could be considered the reference embolizing agent to
use as a comparator.
We are conducting a randomised trial of TAE vs. TACE with
PVA particles in both arms (http://public.ukcrn.org.uk/Search/
StudyDetail.aspx?StudyID=1495), scheduling 3-week embolisa-
tions to ﬁt into the oncological principles of the use of chemo-
therapy and cell cycle [4]. We believe optimal TAE or TACE
should be evaluated fully, before ‘‘jumping” to the much more
expensive DEB as a standard transarterial therapy.Journal of Hepatology 2Conﬂict of Interest
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